JAK inhibitor with immunosuppressive therapy for severe aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new JAK inhibitor drug combined with intensive immunosuppressive therapy (drugs that calm the immune system) for people with severe aplastic anemia, especially those who haven't improved with standard treatments. It aims to see if adding this new drug can help the bone marrow recover and make more blood cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with severe aplastic anemia (SAA), a condition where your bone marrow stops making enough blood cells.
- If you are in the first part of the study (Phase Ib), you must have already tried standard immunosuppressive therapy plus a platelet-boosting drug for at least 4 months, and it didn't work or the disease came back.
- If you are in the second part (Phase II), you must have severe disease that meets specific blood count and bone marrow criteria, and you must not have had certain prior treatments like ATG, cyclosporine, or a platelet-boosting drug for more than a month.
- You are 18 years or older and are not suitable for, or you choose not to have, a bone marrow transplant.
- You must be generally able to care for yourself (ECOG performance status 0-2).
- You do not have other bone marrow disorders, active infections (like HIV, hepatitis, or tuberculosis), uncontrolled bleeding, or a history of blood clots or certain cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral JAK1 inhibitor called golidocitnib for people with T/NK-cell lymphoma that came back after treatment or didn't respond. The drug works by blocking a signal that helps cancer cells grow.
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
This study tests an investigational pill (golidocitinib) for people whose interstitial lung disease is getting worse quickly, despite needing steroids. The goal is to see if this drug can help slow or stop the rapid decline in lung function.
This trial tests a new drug, golidocitinib, to treat severe low blood cell counts caused by immunotherapy in people with advanced lung cancer. It aims to help your blood recover so you can continue cancer treatment and feel better.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This study tests a new daily pill called golidocitinib for adults with immune thrombocytopenia (ITP) — a condition where the immune system attacks platelets, leading to low counts and bleeding risk. The drug aims to lower that immune attack and raise platelet counts, and may help people who have not had lasting success with other treatments.
Hear when a new Severe Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.